Trial
NCT04466917
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
Parexel
Condition
Metastatic Non-small Cell Lung Cancer (NSCLC)
Intervention
ABP 215
Why stopped
Sponsor decision to early terminate the study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-03